Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AUPH Aurinia Pharmaceuticals

Market Closed 11-01 16:00:00 EDT

7.32

+0.11

+1.53%

盘后7.32

+0.000.00%

19:35 EDT

High7.37	Low7.16	Vol821.00K
Open7.20	D1 Closing7.21	Amplitude2.91%
Mkt Cap1.05B	Tradable Cap941.20M	Total Shares142.99M
T/O5.99M	T/O Rate0.64%	Tradable Shares128.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"AUPH","market":"US","secType":"STK","nameCN":"Aurinia Pharmaceuticals","latestPrice":7.32,"timestamp":1730491200000,"preClose":7.21,"halted":0,"volume":821000,"hourTrading":{"tag":"盘后","latestPrice":7.32,"preClose":7.32,"latestTime":"19:35 EDT","volume":78931,"amount":577774.395,"timestamp":1730504150201},"delay":0,"floatShares":128579685,"shares":142990974,"eps":-0.354683,"marketStatus":"Market Closed","change":0.11,"latestTime":"11-01 16:00:00 EDT","open":7.2,"high":7.37,"low":7.16,"amount":5988356.5127,"amplitude":0.029126,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.354683,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1730710800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":951454800000,"exchange":"NASDAQ","adjPreClose":7.21,"preHourTrading":{"tag":"盘前","latestPrice":7.1103,"preClose":7.21,"latestTime":"09:25 EDT","volume":65109,"amount":469422.347328,"timestamp":1730467532879},"postHourTrading":{"tag":"盘后","latestPrice":7.32,"preClose":7.32,"latestTime":"19:35 EDT","volume":78931,"amount":577774.395,"timestamp":1730504150201},"volumeRatio":0.920619808241917,"impliedVol":0.363,"impliedVolPercentile":0.0635},"requestUrl":"/m/hq/s/AUPH/tweets","defaultTab":"tweets","newsList":[{"id":"2480206638","title":"Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years ago","url":"https://stock-news.laohu8.com/highlight/detail?id=2480206638","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480206638?lang=en_us&edition=fundamental","pubTime":"2024-11-02 22:36","pubTimestamp":1730558164,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc.  shareholders will doubtless be very grateful to see the share price up 33% in the last quarter. But the last three years have seen a terrible decline. Indeed, the share price is down a whopping 77% in the last three years. Arguably, the recent bounce is to be expected after such a bad drop. Of course the real question is whether the business can sustain a turnaround.Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns.Check out our latest analysis for Aurinia Pharmaceuticals. Over three years, Aurinia Pharmaceuticals grew revenue at 43% per year. That's well above most other pre-profit companies. So on the face of it we're really surprised to see the share price down 21% a year in the same time period. The share price makes us wonder if there is an issue with profitability. Ultimately, revenue growth doesn't amount to much if the business can't scale we","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shareholders-aurinia-pharmaceuticals-nasdaq-auph-143604583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B3QW5Z07.USD","IE00B64PRP62.GBP","QLD","TQQQ","SQQQ","BK4139","AUPH","PSQ","LU2210150020.SGD","QID","BK4585","BK4112","NQmain","LU2210149790.SGD","MNQmain","IE00BKPKM429.USD",".IXIC","BK4588","NDAQ","LU2095319765.USD","IE00BGHQF748.EUR"],"gpt_icon":1},{"id":"2479974750","title":"Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2479974750","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479974750?lang=en_us&edition=fundamental","pubTime":"2024-10-31 04:05","pubTimestamp":1730318700,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. & EDMONTON, Alberta, October 30, 2024----Aurinia Pharmaceuticals Inc.   today announced that it will release financial and operational results for the third quarter of 2024 before markets open on November 7, 2024.Aurinia’s management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update.The link to the audio webcast is available here. To join the conference call, please dial  715-9871 / +1  307-1963. Conference ID: 6251719 or company name required for entry. A replay of the webcast will be available on Aurinia’s website.Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS , the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differen","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OLSNBVyd5G4ZtpkRpRDugA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/58fdc57fe1de779c255ac2278dd13d7c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OLSNBVyd5G4ZtpkRpRDugA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/58fdc57fe1de779c255ac2278dd13d7c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aurinia-pharmaceuticals-release-third-quarter-200500525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","AUPH"],"gpt_icon":1},{"id":"2479283062","title":"Aurinia Pharmaceuticals Inc  expected to post earnings of 2 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2479283062","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479283062?lang=en_us&edition=fundamental","pubTime":"2024-10-29 21:43","pubTimestamp":1730209409,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc  expected to post earnings of2cents a share - Earnings Preview Aurinia Pharmaceuticals Inc AUPH.OQ AUPH.O is expected to show a rise in quarterly revenue when it reports  r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nL8N3M5200:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Aurinia Pharmaceuticals Inc  expected to post earnings of 2 cents a share - Earnings Preview","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH"],"gpt_icon":0},{"id":"2474069772","title":"Aurinia Pharmaceuticals Showcases LUPKYNIS’s Impact at ASN 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2474069772","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474069772?lang=en_us&edition=fundamental","pubTime":"2024-10-11 18:32","pubTimestamp":1728642740,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals Inc. presented new data at ASN Kidney Week 2024, highlighting the ef...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aurinia-pharmaceuticals-showcases-lupkyniss-impact-at-asn-2024?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aurinia-pharmaceuticals-showcases-lupkyniss-impact-at-asn-2024?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH","BK4139"],"gpt_icon":0},{"id":"2474652870","title":"Aurinia Presents New Data Highlighting Real-World Utilization and Value of Lupkynis® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2474652870","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474652870?lang=en_us&edition=fundamental","pubTime":"2024-10-11 18:00","pubTimestamp":1728640800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241011:nTUA6WG6KQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AUPH","BK4139"],"gpt_icon":0},{"id":"2474066953","title":"Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2474066953","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474066953?lang=en_us&edition=fundamental","pubTime":"2024-10-11 18:00","pubTimestamp":1728640800,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. & EDMONTON, Alberta, October 11, 2024----Aurinia Pharmaceuticals Inc.  , announced today the acceptance of six abstracts, including five poster presentations, at the American Society of Nephrology  Kidney Week 2024 taking place in San Diego, CA October 23-27. These data reinforce the clinical importance of LUPKYNIS , a second generation calcineurin inhibitor , for the treatment of adults with active lupus nephritis .\"The data featured at ASN elucidate the critical role LUPKYNIS plays in advancing the treatment of lupus nephritis, especially in populations disproportionately impacted by the disease. We’re particularly excited about moving our ENLIGHT-LN registry forward, as clinicians need insights into real-world treatment patterns. Additionally, we continue adding to our growing body of evidence that the unique mechanism of action of LUPKYNIS affects podocytes, resulting in significant impact on kidney health in adults with active LN,\" said Dr. Greg Keenan, Chief Medica","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/54Lk5Vq_6yhHzjjTps9VFQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/219f5f82c3930d97554b8d443992c25d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/54Lk5Vq_6yhHzjjTps9VFQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/219f5f82c3930d97554b8d443992c25d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aurinia-presents-data-highlighting-real-100000043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNI","TAC","BK4105","BK4077","BK4016","BK4139","AFG","SLE","BK4107","AUPH","BK4117"],"gpt_icon":0},{"id":"2470083025","title":"Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2470083025","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470083025?lang=en_us&edition=fundamental","pubTime":"2024-09-27 20:47","pubTimestamp":1727441273,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Aurinia Pharmaceuticals Inc.'s  future prospects. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. With the latest financial year loss of US$78m and a trailing-twelve-month loss of US$50m, the US$1.0b market-cap company alleviated its loss by moving closer towards its target of breakeven. As path to profitability is the topic on Aurinia Pharmaceuticals' investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.Check out our latest analysis for Aurinia Pharmaceuticals. According to the 7 industry analysts covering Aurinia Pharmaceuticals, the consensus is that breakeven is near. They expect the company to post a final loss ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aurinia-pharmaceuticals-inc-nasdaq-auph-124753826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B3QW5Z07.USD","BK4585","LU2210150020.SGD","NDAQ","BK4588","SQQQ","MNQmain","IE00B64PRP62.GBP","TQQQ","LU2095319765.USD","BK4112","AUPH","LU2210149790.SGD","BK4139",".IXIC","QLD","IE00BKPKM429.USD","PSQ","QID","NQmain","IE00BGHQF748.EUR"],"gpt_icon":1},{"id":"2470737669","title":"Aurinia Pharmaceuticals: Strategic Growth and Buy Rating Amidst Japan Market Expansion and M&A Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2470737669","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470737669?lang=en_us&edition=fundamental","pubTime":"2024-09-26 22:05","pubTimestamp":1727359551,"startTime":"0","endTime":"0","summary":"Analyst David Martin PhD from Bloom Burton maintained a Buy rating on Aurinia Pharmaceuticals (AUPH – Research Report) and increased the price targ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/aurinia-pharmaceuticals-strategic-growth-and-buy-rating-amidst-japan-market-expansion-and-ma-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/aurinia-pharmaceuticals-strategic-growth-and-buy-rating-amidst-japan-market-expansion-and-ma-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH"],"gpt_icon":0},{"id":"2469490399","title":"Aurinia Pharmaceuticals Says Lupus Nephritis Treatment Gets Japan's Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2469490399","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469490399?lang=en_us&edition=fundamental","pubTime":"2024-09-24 22:38","pubTimestamp":1727188736,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals  said Japan's Ministry of Health, Labor and Welfare approved voclosporin in combination with mycophenolate mofetil to treat lupus nephritis.The approval is based on efficacy and safety data of voclosporin, which is available in the US under the brand name Lupkynis, Aurinia said Tuesday in a statement.The company said its collaboration partner, Otsuka Pharmaceutical, filed the new drug application in Japan in November.Price: 6.84, Change: -0.14, Percent Change: -2.02","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"2469243493","title":"BRIEF-Aurinia Announces Japan Approval Of Lupkynis (Voclosporin) To Treat Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2469243493","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469243493?lang=en_us&edition=fundamental","pubTime":"2024-09-24 20:48","pubTimestamp":1727182081,"startTime":"0","endTime":"0","summary":"Sept 24 (Reuters) - Aurinia Pharmaceuticals Inc :   * AURINIA ANNOUNCES JAPAN APPROVAL OF LUPKYNIS® (VOCLOSPORIN) TO TREAT LUPUS NEPHRITISSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"gpt_icon":0},{"id":"2469549324","title":"Aurinia’s Lupus Drug LUPKYNIS Wins Approval in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2469549324","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469549324?lang=en_us&edition=fundamental","pubTime":"2024-09-24 20:43","pubTimestamp":1727181781,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals Inc. celebrates the Japanese approval of LUPKYNIS (voclosporin) to t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aurinias-lupus-drug-lupkynis-wins-approval-in-japan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aurinias-lupus-drug-lupkynis-wins-approval-in-japan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH","BK4139"],"gpt_icon":0},{"id":"2469498975","title":"Aurinia Pharma Gets Approval in Japan for Lupus Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2469498975","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469498975?lang=en_us&edition=fundamental","pubTime":"2024-09-24 20:28","pubTimestamp":1727180880,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals said Japanese regulators have approved its drug voclosporin in a combination treatment for lupus.The company said Tuesday that the Japanese Ministry of Health, Labour, and Welfare has authorized voclosporin to be used in combination with mycophenolate mofetil to treat lupus nephritis.The approval is based on data from a recent Phase 3 study that assessed the efficacy and safety of the combination.Aurinia's collaboration partner Otsuka Pharmaceutical filed a new drug application for the treatment last November.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"2469605254","title":"Aurinia Announces Japan Approval of Lupkynis® (Voclosporin) to Treat Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2469605254","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469605254?lang=en_us&edition=fundamental","pubTime":"2024-09-24 20:10","pubTimestamp":1727179800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240924:nTUA3VZXNR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"2469460128","title":"Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2469460128","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469460128?lang=en_us&edition=fundamental","pubTime":"2024-09-24 20:10","pubTimestamp":1727179800,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. & EDMONTON, Alberta, September 24, 2024----Aurinia Pharmaceuticals Inc.   today announced that the Japanese Ministry of Health, Labour, and Welfare has approved voclosporin, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil  to treat lupus nephritis .\"We are thrilled to achieve this milestone that will provide access to LUPKYNIS in Japan, where there is a high rate of lupus nephritis among Japanese lupus patients. Our successful strategic partnership with Otsuka has allowed us to bring LUPKYNIS to LN patients across Europe and now Japan, addressing a significant unmet need,\" said Peter Greenleaf, President, and Chief Executive Officer of Aurinia.Medical guidelines recommend that all SLE patients receive routine LN screenings at every visit. Guidelines also note that delaying LN diagnosis has profound prognostic repercussions. Yet, research shows that approximately 50% of SLE patients are not screened for LN and 77% of people with LN go ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/WiI5We4_nCBDRZl2.sVhfw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/88f230b1295da02610e45dd40f668133","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/WiI5We4_nCBDRZl2.sVhfw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/88f230b1295da02610e45dd40f668133"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aurinia-announces-japan-approval-lupkynis-121000760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4077","SLE","CNI","BK4016","AUPH","BK4139"],"gpt_icon":0},{"id":"2468730805","title":"Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2468730805","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468730805?lang=en_us&edition=fundamental","pubTime":"2024-09-19 19:55","pubTimestamp":1726746929,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals' LUPKYNIS, an FDA-approved treatment for lupus nephritis, is well-positioned to become a new standard of care due to its dual role in immunosuppression and kidney protection.The partnership with Otsuka Pharmaceutical supports Aurinia's international expansion into European and Asian markets.AUR200, now in Phase 1 trials, could be a significant future value driver targeting autoimmune diseases.Aurinia has strong financials with ample resources, positive cash flow, and trades at a compelling valuation.Although AUPH is highly dependent on LUPKYNIS, the company's growth prospects justify a \"strong-buy\" rating for investors aware of market adoption risks.   Maks_Lab Aurinia Pharmaceuticals Inc.  is a biopharmaceutical company focused on autoimmune diseases. Currently, AUPH’s hit product is LUPKYNIS, which is indicated for managing lupus nephritis [LN]. LN is a complication of systemic lupus erythematosus [SLE]. Thus, LUPKYNIS is an FDA-approved treatment for LN that ","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1368834736/image_1368834736.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1368834736/image_1368834736.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4722040-aurinia-pharmaceuticals-lupkynis-leading-the-way-in-lupus-nephritis-treatment","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["AUPH","BK4139"],"gpt_icon":0},{"id":"2468040300","title":"Aurinia Pharmaceuticals: This Recovery Can Continue","url":"https://stock-news.laohu8.com/highlight/detail?id=2468040300","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468040300?lang=en_us&edition=fundamental","pubTime":"2024-09-18 16:41","pubTimestamp":1726648899,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals shows promising growth with increased Lupkynis sales. The near future could see a $10M milestone for Japanese approval and royalty payments from Japanese sales.AUPH is developing AUR200, with a phase 1 trial underway allowing it to diversify beyond Lupkynis.The Company reported a $722K net income for Q2'24, up from a $10.7M net loss in Q1'24.   smshoot/iStock via Getty Images When I last covered Aurinia Pharmaceuticals   in May, I rated the company a buy, as sales of Lupkynis seemed to have renewed growth. In the past two months, AUPH has; restructured its board, made moves","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1705819656/image_1705819656.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1705819656/image_1705819656.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4721762-aurinia-pharmaceuticals-stock-this-recovery-can-continue","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["AUPH","BK4139"],"gpt_icon":0},{"id":"2467442368","title":"Aurinia Pharmaceuticals Price Target Maintained With a $10.00/Share by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2467442368","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467442368?lang=en_us&edition=fundamental","pubTime":"2024-09-16 23:31","pubTimestamp":1726500660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AUPH/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 16, 2024 11:31 ET (15:31 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH"],"gpt_icon":0},{"id":"2467677098","title":"BUZZ-Aurinia Pharmaceuticals jumps after Tang Capital reports 5.1% stake in co","url":"https://stock-news.laohu8.com/highlight/detail?id=2467677098","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467677098?lang=en_us&edition=fundamental","pubTime":"2024-09-13 23:52","pubTimestamp":1726242755,"startTime":"0","endTime":"0","summary":"** U.S.-listed shares of drugmaker Aurinia Pharmaceuticals  up 6.6% at $7.01   ** Tang Capital Management reports 5.1% stake in AUPH as of Sept. 6   ** Separately, AUPH said on Thursday it has restruc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMH","BK4139","BK4112","AUPH"],"gpt_icon":0},{"id":"2467896777","title":"Aurinia Pharmaceuticals Shares up 8.9% After Tang Capital Management Reports 5.1% Stake in Co as of September 6","url":"https://stock-news.laohu8.com/highlight/detail?id=2467896777","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467896777?lang=en_us&edition=fundamental","pubTime":"2024-09-13 23:29","pubTimestamp":1726241367,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240913:nL4N3KV1BU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AUPH","BK4139"],"gpt_icon":0},{"id":"2467972161","title":"Aurinia Pharmaceuticals Shares up 5.3% Premarket After Tang Capital Management Reports 5.1% Stake in Co as of September 6","url":"https://stock-news.laohu8.com/highlight/detail?id=2467972161","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467972161?lang=en_us&edition=fundamental","pubTime":"2024-09-13 20:07","pubTimestamp":1726229264,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240913:nFWN3KV0HJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AUPH","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.auriniapharma.com","stockEarnings":[{"period":"1week","weight":0.0383},{"period":"1month","weight":0.0281},{"period":"3month","weight":0.3309},{"period":"6month","weight":0.4353},{"period":"1year","weight":-0.0711},{"period":"ytd","weight":-0.1858}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":0.0038},{"period":"3month","weight":0.0716},{"period":"6month","weight":0.1169},{"period":"1year","weight":0.3257},{"period":"ytd","weight":0.2014}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.106403},{"month":2,"riseRate":0.5,"avgChangeRate":0.009372},{"month":3,"riseRate":0.4,"avgChangeRate":0.102117},{"month":4,"riseRate":0.6,"avgChangeRate":-0.012088},{"month":5,"riseRate":0.6,"avgChangeRate":-0.004093},{"month":6,"riseRate":0.4,"avgChangeRate":-0.030211},{"month":7,"riseRate":0.6,"avgChangeRate":0.036556},{"month":8,"riseRate":0.5,"avgChangeRate":-0.045687},{"month":9,"riseRate":0.5,"avgChangeRate":0.078058},{"month":10,"riseRate":0.545455,"avgChangeRate":0.035973},{"month":11,"riseRate":0.545455,"avgChangeRate":-0.000066},{"month":12,"riseRate":0.4,"avgChangeRate":0.111111}],"exchange":"NASDAQ","name":"Aurinia Pharmaceuticals","nameEN":"Aurinia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aurinia Pharmaceuticals(AUPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aurinia Pharmaceuticals,AUPH,Aurinia Pharmaceuticals股票,Aurinia Pharmaceuticals股票老虎,Aurinia Pharmaceuticals股票老虎国际,Aurinia Pharmaceuticals行情,Aurinia Pharmaceuticals股票行情,Aurinia Pharmaceuticals股价,Aurinia Pharmaceuticals股市,Aurinia Pharmaceuticals股票价格,Aurinia Pharmaceuticals股票交易,Aurinia Pharmaceuticals股票购买,Aurinia Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aurinia Pharmaceuticals(AUPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction